Effect of extending the platelet storage time on platelet utilization: predictions from a mathematical model of

A Pereira1, C Sanz

  • 1Service of Haemotherapy and Haemostasis, Hospital Clínic, Barcelona, Spain. apereira@clinic.ub.es

Insights

Extending platelet (PLT) storage using bacterial culturing (BCU) or photochemical treatment (PCT) increases PLT transfusions. This intensive usage may paradoxically lead to more time with low platelet counts, especially in complex patient cases.

Area of Science:

  • Transfusion Medicine
  • Hematology
  • Biotechnology

Background:

  • Extending platelet concentrate shelf-life is desirable for inventory management.
  • Bacterial culturing (BCU) and photochemical treatment (PCT) are methods to extend platelet storage to 7 days.
  • These methods may reduce post-transfusion platelet viability and recovery.

Purpose of the Study:

  • To predict the impact of extended platelet shelf-life on the management of patients receiving prophylactic platelet support.
  • To model the dynamics of platelet support under different storage conditions.

Main Methods:

  • A mathematical model simulating prophylactic platelet support was developed.
  • Data on post-transfusion platelet kinetics and treatment effects were sourced from published literature.
  • Key variables included transfusion timing, PCT use, and synergistic effects on platelet consumption.

Main Results:

  • Extending shelf-life to 7 days increased platelet transfusions by 9% (BCU) and 19% (PCT) in the reference scenario.
  • In worst-case scenarios, increases reached 27% (BCU) and 38% (PCT).
  • Despite increased usage, time spent with platelet counts below 10 x 10(9)/L often increased.

Conclusions:

  • Extending platelet shelf-life significantly increases overall platelet usage.
  • Potential synergistic interactions between extended storage/PCT and clinical factors may disproportionately increase usage in complex patients.
  • Further clinical research is needed to understand these interactions and optimize patient management.

Related Concept Videos

Formation of the Platelet Plug01:22

Formation of the Platelet Plug

The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
Structure and Function of Platelets01:18

Structure and Function of Platelets

The cell fragments known as platelets are disc-shaped, with an average diameter of about 3 μm and a thickness of roughly 1 μm. They play a crucial role in the body's vascular clotting system, which also involves plasma proteins, blood cells, and blood vessel tissues.
Platelets are continually replenished, circulating in the bloodstream for 9-12 days before being removed by phagocytes, primarily in the spleen. A microliter of circulating blood contains between 150,000 and 450,000 platelets, with...
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions01:15

Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions

PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure (CHF).